Evofem Biosciences, Inc.
EVFM- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001618835
No open-market purchases or sales by Evofem Biosciences, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Evofem Biosciences, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 104 | 83 | −21 |
| Shares | 42.6M | 36.2M | −6.37M (−15.0%) |
| Value | $74.6M | $40.9M | −$33.6M (−45.1%) |
New holders (17)
Institutions that held Evofem Biosciences, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 1,507,888 | $1.70M | 0.00% |
| Group One Trading, L.P. | 529,650 | $599.0K | 0.01% |
| Ergoteles LLC | 349,700 | $395.0K | 0.01% |
| Parallax Volatility Advisers, L.P. | 105,294 | $119.0K | 0.00% |
| LMR Partners LLP | 47,626 | $54.0K | 0.00% |
| Boothbay Fund Management, LLC | 20,659 | $23.0K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 18,815 | $21.0K | 0.01% |
| Raymond James & Associates | 15,248 | $17.0K | 0.00% |
| Congress Park Capital LLC | 14,500 | $16.0K | 0.01% |
| Platform Technology Partners | 13,000 | $15.0K | 0.01% |
| Squarepoint Ops LLC | 11,271 | $13.0K | 0.00% |
| Mirador Capital Partners LP | 10,185 | $12.0K | 0.00% |
| Advisor Resource Council | 10,000 | $11.0K | 0.00% |
| HHM Wealth Advisors, LLC | 1,902 | $2.00K | 0.00% |
| The PNC Financial Services Group, Inc. | 1,000 | $1.00K | 0.00% |
| Strategic Blueprint, LLC | 102 | $0 | 0.00% |
| Westside Investment Management, Inc. | 10,000 | – | – |
Sold out (38)
Institutions that held Evofem Biosciences, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.